原始来源记录
重大申请已提交
Spruce Biosciences 计划于 2026 年第四季度提交 TA-ERT 的 BLA
Spruce 表示正在推进生产、监管互动和商业规划，以支持计划于 2026 年第四季度提交 TA-ERT 的 BLA。该申请将是 MPS IIIB 疾病修饰疗法的首个监管申请，目前该病尚无获批治疗方案。公司还披露现金储备已加强，可维持至 2027 年下半年，以覆盖提交及潜在获批所需。
关键事实
- 申报时间
- 2026年5月13日 12:05
- 事件
- 申请已提交
- 方向
- 中性
- 来源
- SEC 8-K
- 可信度
- 有来源
来源摘录
EX-99.1 2 sprb-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Spruce Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates Long-Term TA-ERT Data Presented at the 22nd Annual WORLDSymposium™ Highlight Rapid and Durable Reduction of Heparan Sulfate and Stabilization of Cognitive Function in Patients with MPS IIIB Strengthened Leadership Team Across Commercial, Clinical Development, and Regulatory Functions to Support BLA Submission and Pre-Launch Readiness Closed Underwritten Public Offering for $69.0 Million in Gross Proceeds, Extending Cash Runway into the Second Half of 2027 and Beyond Anticipated Potential FDA Approval of TA-ERT Entered into Loan and Security Agreement with Avenue Capital for up to $50.0 Million in Term Loans to Strengthen Financial Flexibil